Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the challenges and advancements in treating acute myeloid leukemia (AML) in patients who are unfit for intensive…
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, discusses a study evaluating the efficacy of combining venetoclax with hypomethylating agents in treating patients with acute myeloid leukemia…
NEW YORK (Reuters Health) – Women who regularly use nonsteroidal anti-inflammatory drugs (NSAIDs) have better survival after a colorectal cancer (CRC) diagnosis, research indicates. “A wide body of…
NEW YORK (Reuters Health) – In patients with newly diagnosed multiple myeloma, combining the thalidomide analog lenalidomide with low-dose dexamethasone led to better short-term survival than lenalidomide plus…
NEW YORK (Reuters Health) – Iatrogenic preterm delivery is common among women diagnosed with invasive cancer during pregnancy, a new multicenter study shows. The study, published online in…
NEW YORK (Reuters Health) – Adult survivors of childhood cancer, particularly those in poor physical health, are at increased risk for suicidal thoughts, according to an October 19…
NEW YORK (Reuters Health) – Neoadjuvant treatment with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor, can help downstage bladder cancer to organ-confined disease, thereby increasing the…
NEW YORK (Reuters Health) – Treatment with the third generation bisphosphonate zoledronic acid (Zometa) may improve survival in lung cancer patients with bone metastases, Greek researchers report. Between…
NEW YORK (Reuters Health) – While minimally invasive radical prostatectomy (MIRP) offers certain advantages over open retropubic radical prostatectomy (RRP), such as a shorter hospital stay, it also…
NEW YORK (Reuters Health) – Tamoxifen therapy has been linked to an increased risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) and now new research suggests…
NEW YORK (Reuters Health) – In patients receiving first-line treatment for metastatic colon cancer, planned complete discontinuation of chemotherapy had a negative impact on duration of disease control…
NEW YORK (Reuters Health) – In a phase III trial in women with HER2/hormone receptor-copositive metastatic breast cancer, the combination of trastuzumab plus anastrozole improved outcomes compared to…
